US Dollar vs Yen

登録してリアルタイムのチャート、分析ツール、価格を入手してください。

登録

ホーム
投資
株式
アメリカ
NASDAQ
Inhibikase Therapeutics Inc (IKT)
Inhibikase Therapeutics Inc (IKT) ニュース

IKT

Inhibikase Therapeutics (IKT)

Inhibikase Therapeutics Inc

から:

Regulatory News

Text Search:

次の項目別のソート:

Non-Regulatory News

Showing the most relevant articles for your search:NASDAQ:IKT

1 2 3 4 5 6 7 次へ >>

日付	受信時刻	ニュースソース	見出し	コード	企業名
2024/05/16	09 : 00	GlobeNewswire Inc.	Inhibikase Therapeutics Reports First Quarter Financial Results and Highlights Recent Period Activity	NASDAQ:IKT	Inhibikase Therapeutics Inc
2024/05/16	06 : 04	Edgar (US Regulatory)	Form 10-Q - Quarterly report [Sections 13 or 15(d)]	NASDAQ:IKT	Inhibikase Therapeutics Inc
2024/05/15	21 : 45	GlobeNewswire Inc.	Inhibikase Therapeutics Announces Request for Withdrawal of S-1 Registration Statement	NASDAQ:IKT	Inhibikase Therapeutics Inc
2024/05/15	20 : 56	Edgar (US Regulatory)	Form RW - Registration Withdrawal Request	NASDAQ:IKT	Inhibikase Therapeutics Inc
2024/05/10	03 : 41	Edgar (US Regulatory)	Form S-1/A - General form for registration of securities under the Securities Act of 1933: [Amend]	NASDAQ:IKT	Inhibikase Therapeutics Inc
2024/05/09	21 : 00	GlobeNewswire Inc.	Inhibikase Therapeutics Announces Final Pre-IND Meeting Outcomes for IkT-001Pro as a Treatment for Pulmonary Arterial Hypertension	NASDAQ:IKT	Inhibikase Therapeutics Inc
2024/04/19	05 : 30	GlobeNewswire Inc.	Inhibikase Therapeutics Issues Letter to Shareholders and Provides Update on Development Programs	NASDAQ:IKT	Inhibikase Therapeutics Inc
2024/04/03	21 : 05	GlobeNewswire Inc.	Inhibikase Therapeutics Announces Pre-IND Meeting with the FDA for IkT-001Pro in Pulmonary Arterial Hypertension	NASDAQ:IKT	Inhibikase Therapeutics Inc
2024/03/28	05 : 15	GlobeNewswire Inc.	Inhibikase Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Activity	NASDAQ:IKT	Inhibikase Therapeutics Inc
2024/03/07	22 : 30	GlobeNewswire Inc.	Inhibikase Therapeutics to Provide Trial Update for Risvodetinib at the 2024 International Conference on Alzheimer’s and Parkinson’s Diseases and Related Neurological Disorders	NASDAQ:IKT	Inhibikase Therapeutics Inc
2024/02/29	06 : 05	GlobeNewswire Inc.	Inhibikase Therapeutics Announces Full Outcomes of its Pre-NDA Meeting with the FDA for IkT-001Pro	NASDAQ:IKT	Inhibikase Therapeutics Inc
2024/02/07	21 : 59	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:IKT	Inhibikase Therapeutics Inc
2024/02/07	21 : 55	GlobeNewswire Inc.	Inhibikase Therapeutics Announces Preliminary Outcomes of its Pre-NDA Meeting with the FDA on the Pathway for Approval for IkT-001Pro in Blood and Gastrointestinal Cancers	NASDAQ:IKT	Inhibikase Therapeutics Inc
2024/02/02	06 : 49	Edgar (US Regulatory)	Form 424B5 - Prospectus [Rule 424(b)(5)]	NASDAQ:IKT	Inhibikase Therapeutics Inc
2024/02/02	06 : 09	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:IKT	Inhibikase Therapeutics Inc
2024/01/29	23 : 05	GlobeNewswire Inc.	Inhibikase Therapeutics Announces Publication Highlighting Results from its Phase 1 Studies with Risvodetinib	NASDAQ:IKT	Inhibikase Therapeutics Inc
2024/01/17	06 : 31	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:IKT	Inhibikase Therapeutics Inc
2024/01/17	06 : 05	GlobeNewswire Inc.	Inhibikase Therapeutics Announces Planned Retirement of Chief Financial Officer Joseph Frattaroli	NASDAQ:IKT	Inhibikase Therapeutics Inc
2023/12/19	22 : 30	GlobeNewswire Inc.	Inhibikase Therapeutics Issues Letter to Shareholders and Provides Update on Development Programs	NASDAQ:IKT	Inhibikase Therapeutics Inc
2023/12/04	22 : 35	GlobeNewswire Inc.	Inhibikase Therapeutics Granted Pre-NDA Meeting with the FDA for IkT-001Pro	NASDAQ:IKT	Inhibikase Therapeutics Inc
2023/11/15	06 : 30	GlobeNewswire Inc.	Inhibikase Therapeutics Reports Third Quarter Financial Results and Highlights Recent Period Activity	NASDAQ:IKT	Inhibikase Therapeutics Inc
2023/11/07	23 : 28	GlobeNewswire Inc.	Correcting & Replacing -- Inhibikase Therapeutics to Report Third Quarter Financial Results on November 14, 2023	NASDAQ:IKT	Inhibikase Therapeutics Inc
2023/11/07	22 : 00	GlobeNewswire Inc.	Inhibikase Therapeutics to Report Second Quarter Financial Results on November 14, 2023	NASDAQ:IKT	Inhibikase Therapeutics Inc
2023/10/17	06 : 24	Edgar (US Regulatory)	Form 10-K/A - Annual report [Section 13 and 15(d), not S-K Item 405]: [Amend]	NASDAQ:IKT	Inhibikase Therapeutics Inc
2023/10/16	20 : 00	GlobeNewswire Inc.	Inhibikase Therapeutics Highlights Unblinded Functional Analysis from the 201 Trial of Risvodetinib in Untreated Parkinson’s Disease and Provides Update on Ongoing Enrollment	NASDAQ:IKT	Inhibikase Therapeutics Inc
2023/10/04	21 : 30	GlobeNewswire Inc.	Inhibikase Therapeutics Receives FDA Orphan Drug Designation for Risvodetinib for the Treatment of Multiple System Atrophy	NASDAQ:IKT	Inhibikase Therapeutics Inc
2023/09/21	00 : 23	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:IKT	Inhibikase Therapeutics Inc
2023/08/24	21 : 30	PR Newswire (US)	Inhibikase Therapeutics Announces Development of Novel Formulation of risvodetinib	NASDAQ:IKT	Inhibikase Therapeutics Inc
2023/08/22	21 : 05	PR Newswire (US)	Inhibikase Therapeutics to Present at the International Congress of Parkinson's Disease and Movement Disorders	NASDAQ:IKT	Inhibikase Therapeutics Inc
2023/08/21	21 : 30	PR Newswire (US)	Inhibikase Therapeutics Initiates Development of Second Generation c-Abl inhibitors and names IkT-148009 as risvodetinib	NASDAQ:IKT	Inhibikase Therapeutics Inc

Showing the most relevant articles for your search:NASDAQ:IKT

1 2 3 4 5 6 7 次へ >>

US Global Investors Funds US Gov

Vontobel Financial Produ...

Bloom Health Partners

Morgan Stanley Finance L...

Franklin Conservative Al...

Amundi Index Solutions

Principal Real Estate Se...

INTESA SANPAOLO

Vontobel Financial Produ...

Delayed Upgrade Clock

顧客サポート: +44 (0) 203 8794 460 | support@advfn.com

ADVFNのサービスをご利用いただくには、利用規約